GoodRx Holdings, Inc.
GDRXHealthcareNASDAQHealth Information Services
Scan Results
Daily timeframePart of the healthcare sector, GoodRx Holdings, Inc. (GDRX) is listed under Health Information Services. At a $1.21B market cap, GoodRx Holdings, Inc. ranks as a small-cap company within healthcare. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.
Market Cap
$1.21B
Beta
1.69
P/E (TTM)
70.80
P/E (Fwd)
10.06
EPS (TTM)
$0.05
EPS (Fwd)
$0.35
ROE
2.5%
ROA
3.0%
Cash
$296.1M
Total Debt
$539.0M
Free CF
$112.5M
52W Change
-6.1%
Annual Financials
Cash vs Debt
Where GDRX stands vs its 150-day and 200-day moving averages
As of the October 14, 2026 close, GDRX finished 19.79% above its 150-day moving average ($2.88) and 24.55% above its 200-day moving average ($2.77). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GDRX overbought or oversold?
At the October 14, 2026 close, GDRX's RSI(14) was 59.1, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, GDRX has $296.1M in cash with $539.0M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $112.5M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 2.5% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 3.0% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $766.6M (2022) to $796.9M (2025).
A beta of 1.69 means GDRX is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. No single metric tells the full story. Reviewing GDRX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.